HVO Stock Overview
Operates as a pharmaceutical service and contract research company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.21 |
| 52 Week High | UK£0.32 |
| 52 Week Low | UK£0.18 |
| Beta | 1.05 |
| 1 Month Change | -5.29% |
| 3 Month Change | -26.43% |
| 1 Year Change | -13.26% |
| 3 Year Change | -10.43% |
| 5 Year Change | 285.05% |
| Change since IPO | 202.94% |
Recent News & Updates
Recent updates
hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price
Jan 26
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified
Jan 03At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?
Nov 30A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price
Jun 14A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)
Feb 01Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?
Dec 20Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?
Sep 13Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?
Jun 02Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Feb 15How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
Dec 23Calculating The Fair Value Of Open Orphan plc (LON:ORPH)
Nov 18Shareholder Returns
| HVO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 4.6% | -0.2% | 0.6% |
| 1Y | -13.3% | -32.8% | 2.7% |
Return vs Industry: HVO exceeded the UK Life Sciences industry which returned -32.8% over the past year.
Return vs Market: HVO underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
| HVO volatility | |
|---|---|
| HVO Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HVO's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: HVO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations.
hVIVO plc Fundamentals Summary
| HVO fundamental statistics | |
|---|---|
| Market cap | UK£140.16m |
| Earnings (TTM) | UK£17.45m |
| Revenue (TTM) | UK£67.21m |
8.0x
P/E Ratio2.1x
P/S RatioIs HVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVO income statement (TTM) | |
|---|---|
| Revenue | UK£67.21m |
| Cost of Revenue | UK£50.65m |
| Gross Profit | UK£16.56m |
| Other Expenses | -UK£884.00k |
| Earnings | UK£17.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 24.64% |
| Net Profit Margin | 25.96% |
| Debt/Equity Ratio | 0% |
How did HVO perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 23:21 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
hVIVO plc is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Simms | Arden Partners Plc. |
| Andrew Murray Darley | Cavendish |
| Stuart Harris | Cavendish |